{"id":"revelise-generium-russia","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug mimics the action of endogenous erythropoietin, a hormone that regulates red blood cell production. By activating EPO receptors on erythroid progenitor cells in the bone marrow, it promotes proliferation and differentiation of these cells, leading to increased hemoglobin and hematocrit levels. This mechanism is used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions.","oneSentence":"Revelise is a recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:25.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Chemotherapy-induced anemia"}]},"trialDetails":[{"nctId":"NCT07146360","phase":"PHASE3","title":"Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2014-05-25","conditions":"Myocardial Infarction (MI)","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Revelise (GENERIUM, Russia)","genericName":"Revelise (GENERIUM, Russia)","companyName":"AO GENERIUM","companyId":"ao-generium","modality":"Biologic","firstApprovalDate":"","aiSummary":"Revelise is a recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}